Seelos Therapeutics, Inc.
Seelos Therapeutics is a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
Industries
Nr. of Employees
small (1-50)
Seelos Therapeutics, Inc.
300 Park Avenue, New York, NY 10022
Patents
Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-12239733-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10869831-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10493023-B2
View Details
Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-12239733-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10869831-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10493023-B2
View DetailsProducts
Intranasal racemic ketamine for acute suicidal ideation in MDD and PTSD
An intranasal small-molecule program developed for treating acute suicidal ideation and behavior in major depressive disorder and post-traumatic stress disorder; progressed into clinical study phases with topline data releases.
Gene therapy program for neurological and rare-disease indications
A gene therapy development program targeting CNS or rare-disease biology, undergoing preclinical and translational development.
Intravenous trehalose for neurodegenerative disease
An intravenous formulation of trehalose developed for evaluation in neurodegenerative disease clinical trials, including inclusion in a multi-arm platform trial.
Peptidic inhibitor therapeutic program
A development program advancing peptidic inhibitors as therapeutic candidates for relevant disease targets.
Protein-targeted autophagy therapeutic program
A program developing therapies that target protein homeostasis and autophagy pathways for treatment of neurologic or other diseases driven by protein aggregation.
Intranasal racemic ketamine for acute suicidal ideation in MDD and PTSD
An intranasal small-molecule program developed for treating acute suicidal ideation and behavior in major depressive disorder and post-traumatic stress disorder; progressed into clinical study phases with topline data releases.
Gene therapy program for neurological and rare-disease indications
A gene therapy development program targeting CNS or rare-disease biology, undergoing preclinical and translational development.
Intravenous trehalose for neurodegenerative disease
An intravenous formulation of trehalose developed for evaluation in neurodegenerative disease clinical trials, including inclusion in a multi-arm platform trial.
Peptidic inhibitor therapeutic program
A development program advancing peptidic inhibitors as therapeutic candidates for relevant disease targets.
Protein-targeted autophagy therapeutic program
A program developing therapies that target protein homeostasis and autophagy pathways for treatment of neurologic or other diseases driven by protein aggregation.
Services
Design and conduct of clinical studies including mid-stage (Phase 2) trials and participation in multi-arm platform trials.
Design and conduct of clinical studies including mid-stage (Phase 2) trials and participation in multi-arm platform trials.
Expertise Areas
- CNS therapeutics development
- Rare disease therapeutic development
- Clinical trial management and execution
- Intranasal drug delivery
Key Technologies
- Intranasal drug delivery
- Gene therapy vectors and delivery
- Intravenous formulation development
- Peptide therapeutics